Background: Coffee consumption has been associated with a reduction in breast cancer risk among women with a BRCA1 mutation. The objective of this study was to evaluate whether major contributors of caffeine intake are associated with a reduction in DNA damage and/or oxidative stress in women with and without a BRCA1 mutation. Methods: Coffee, tea, soda and total caffeine consumption was collected by a dietary history questionnaire, and DNA repair capacity in lymphocytes was assessed by the comet assay (tail moments), micronucleus test (per 1,000 binucleated cells) and analysis of γ-H2AX staining (nuclear foci). The thiobarbituric acid-malondialdehyde and DTNB assays were used to estimate serum lipid peroxidation (µmol/l) and protein oxidation (µmol/l), respectively. Results: Among all women, high levels of caffeine and caffeinated coffee intake were associated with significantly lower levels of micronuclei (138.50 vs. 97.67, p = 0.04, and 138.12 vs. 97.70, p = 0.04). There was no significant relationship between caffeine, coffee, tea and soda intake and the other markers of DNA repair capacity and oxidative stress among all women and in analyses stratified by BRCA1 mutation status. Conclusion: The chemopreventive effects of coffee and/or caffeine may be associated with improved capacity to efficiently repair DNA damage.

Keywords:
Breast cancer, Caffeine, DNA repair, Oxidative stress, Coffee, BRCA1
1.
Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-1333.
2.
Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695.
3.
Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
4.
Robson ME: Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer Control 2002;9:457-465.
5.
Thompson D, Easton DF; Breast Cancer Linkage Consortium: Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-1365.
6.
Narod SA: BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010;7:702-707.
7.
Nkondjock A, Ghadirian P, Kotsopoulos J, et al: Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer 2006;118:103-107.
8.
Jiang W, Wu Y, Jiang X: Coffee and caffeine intake and breast cancer risk: an updated dose-response meta-analysis of 37 published studies. Gynecol Oncol 2013;129:620-629.
9.
Devasagayam TP, Kamat JP, Mohan H, et al: Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim Biophys Acta 1996;1282:63-70.
10.
Bøhn SK, Blomhoff R, Paur I: Coffee and cancer risk, epidemiological evidence, and molecular mechanisms. Mol Nutr Food Res 2014;58:915-930.
11.
Mazur W: Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 1998;12:729-742.
12.
Scalbert A, Williamson G: Dietary intake and bioavailability of polyphenols. J Nutr 2000;130(8S suppl):2073S-2085S.
13.
Vinson JA, et al: Vitamins and especially flavonoids in common beverages are powerful in vitro antioxidants which enrich lower density lipoproteins and increase their oxidative resistance after ex vivo spiking in human plasma. J Agric Food Chem 1999;47:2502-2504.
14.
Paur I, Balstad TR, Blomhoff R: Degree of roasting is the main determinant of the effects of coffee on NF-κB and EpRE. Free Radic Biol Med 2010;48:1218-1227.
15.
Boettler U, et al: Induction of antioxidative Nrf2 gene transcription by coffee in humans: depending on genotype? Mol Biol Rep 2012;39:7155-7162.
16.
Vicente SJ, Ishimoto EY, Torres EA: Coffee modulates the transcription factor Nrf2 and highly increases the activity of antioxidant enzymes in rats. J Agric Food Chem 2014;62:116-122.
17.
Volz N, et al: Effect of coffee combining green coffee bean constituents with typical roasting products on the Nrf2/ARE pathway in vitro and in vivo. J Agric Food Chem 2012;60:9631-9641.
18.
Boettler U, Volz N, Pahlke G, et al: Coffees rich in chlorogenic acid or N-methylpyridinium induce chemopreventive phase II-enzymes via the Nrf2/ARE pathway in vitro and in vivo. Mol Nutr Food Res 2011;55:798-802.
19.
Bae I, Fan S, Meng Q, et al: BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 2004;64:7893-7909.
20.
Kotsopoulos J, Shen H, Rao AV, et al: A BRCA1 mutation is not associated with increased indicators of oxidative stress. Clin Breast Cancer 2008;8:506-510.
21.
Gorrini C, Baniasadi PS, Harris IS, et al: BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 2013;210:1529-1544.
22.
Yi YW, Kang HJ, Bae I: BRCA1 and oxidative stress. Cancers (Basel) 2014;6:771-795.
23.
Kotsopoulos J, Chen Z, Vallis KA, et al: DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers. Br J Cancer 2007;96:118-125.
24.
Kotsopoulos J, Chen Z, Vallis KA, et al: Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. Cancer Causes Control 2010;21:679-687.
25.
Csizmadi I, Kahle L, Ullman R, et al: Adaptation and evaluation of the National Cancer Institute's Diet History Questionnaire and nutrient database for Canadian populations. Public Health Nutr 2007;10:88-96.
26.
Singh NP, et al: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-191.
27.
Green MH, Lowe JE, Harcourt SA, et al: UV-C sensitivity of unstimulated and stimulated human lymphocytes from normal and xeroderma pigmentosum donors in the comet assay: a potential diagnostic technique. Mutat Res 1992;273:137-144.
28.
Khan MA, Hill RP, Van Dyk J: Partial volume rat lung irradiation: an evaluation of early DNA damage. Int J Radiat Oncol Biol Phys 1998;40:467-476.
29.
Pilch DR, et al: Characteristics of γ-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003;81:123-129.
30.
Draper HH, et al: A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med 1993;15:353-363.
31.
Jentzsch AM, et al: Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 1996;20:251-256.
32.
Hu ML: Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994;233:380-385.
33.
Foulkes WD, Shuen AY: In brief: BRCA1 and BRCA2. J Pathol 2013;230:347-349.
34.
Cao L, et al: A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell 2009;35:534-541.
35.
Bichler J, Cavin C, Simic T, et al: Coffee consumption protects human lymphocytes against oxidative and 3-amino-1-methyl-5H-pyrido[4,3-b]indole acetate (Trp-P-2) induced DNA-damage: results of an experimental study with human volunteers. Food Chem Toxicol 2007;45:1428-1436.
36.
Ludwig IA, Clifford MN, Lean MEJ, et al: Coffee: biochemistry and potential impact on health. Food Funct 2014;5:1695-1717.
37.
Azam S, et al: Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monit 2003;9:BR325-BR330.
38.
Cardinale F, Bruzzi P, Bolognesi C: Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis. Br J Cancer 2012;106:780-790.
39.
Samanta S, Dey P: Micronucleus and its applications. Diagn Cytopathol 2012;40:84-90.
40.
Niki E: Do antioxidants impair signaling by reactive oxygen species and lipid oxidation products? FEBS Lett 2012;586:3767-3770.
41.
McCall MR, Frei B: Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 1999;26:1034-1053.
42.
Dean RT, et al: Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997;324(Pt 1):1-18.
43.
Collins A, et al: The comet assay as a tool for human biomonitoring studies: the ComNet project. Mutat Res Rev Mutat Res 2014;759:27-39.
44.
Mah LJ, El-Osta A, Karagiannis TC: γH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010;24:679-686.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.